BeiGene Pays $45 Million Upfront for Global Rights to Shoreline Cell Therapies
publication date: Nov 2, 2021
In June of this year, Beijing BeiGene announced a global collaboration to develop and commercialize four natural killer-based cell therapies discovered by San Diego's Shoreline Biosciences. BeiGene made a $45 million upfront payment and will be responsible for (unspecified) milestones, plus additional R&D funding and royalties. Shoreline is developing off-the-shelf, standardized and targeted natural killer and macrophage cellular immunotherapies, which it derives from induced pluripotent stem cells (iPSC), primarily for cancer. Today, Shoreline closed a $140 million B round led by Ally Bridge Group. More details....
Stock Symbols: (NSDQ: BGNE; HK: 06160)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.